Translational Challenges and Opportunities in mRNA Cancer Vaccines
- 1 September 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (9) , 1739-1749
Abstract
Messenger RNA (mRNA) cancer vaccines have progressed rapidly, with personalized platforms such as mRNA-4157 and BNT122 demonstrating feasibility, safety, and durable immune activity but limited scalability. Off-the-shelf constructs, including BNT111 and BNT113, enable faster, broader deployment, yet they risk reduced precision or immune tolerance. These complementary approaches reveal key translational dualities: personalization versus shared antigen (off-the-shelf), potency versus safety, and speed versus durability. This mini-review synthesizes emerging clinical evidence and outlines strategies such as modular vaccine design, prime–boost vaccination regimens, and adaptive trial frameworks to reconcile these trade-offs and advance scalable, durable mRNA vaccines for broad oncologic impact. Significance: By dissecting the competing design pressures that shape mRNA vaccine performance, this mini-review proposes integrative strategies, spanning modular architectures, prime–boost regimens, and adaptive trials, to reconcile immunologic potency with manufacturability and safety, charting a roadmap toward next-generation cancer vaccines.Keywords
Funding Information
- National Cancer Institute (R01CA291876)
- National Cancer Institute (R01CA284108)
- Andrew Sabin Family Foundation (Andrew Sabin Family Excellence Endowment Fund)
This publication has 64 references indexed in Scilit:
- Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagementCell, 2025
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityCell Reports Medicine, 2025
- Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In SituJAMA Oncology, 2025
- Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropismMolecular Therapy - Methods & Clinical Development, 2025
- 877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCCAnnals of Oncology, 2024
- Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory CapabilityAngewandte Chemie International Edition, 2024
- Innate immune mechanisms of mRNA vaccinesImmunity, 2022
- Circular RNA vaccines against SARS-CoV-2 and emerging variantsCell, 2022
- Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle SizePharmaceutical Research, 2022
- Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccinationCell, 2022